Translational cancer research
Our group has been focused for years on the identification, characterization and validation, through multidisciplinary approaches, of prognostic/predictive markers and potential therapeutic targets in tumors, in particular breast, gynecological carcinomas and sarcomas. An additional group goal is to gain insights into the molecular basis of chemo/radioresistance in cancer and to advance in the design of new, more effective and less toxic antitumor (nano)-therapies. Among our studies, we highlight those focused on analyzing the functional role in cancer of the chromosomal instability, cell cycle, mechanisms of cell death, intratumoral heterogeneity and the immune response to tumors.
Milestones
- Patent application: "New nanotherapy for the treatment of breast cancer and brain metastases. Sarrió JD, de la Fuente M, Moreno-Bueno G. EP23382104.0
- Gema Moreno Bueno was appointed member of the Expert Coalition against the triple negative and metastatic breast cancer (CMTNm). Presentation in the European Partlament of the "Manifesto for the research in CMTNm" (Brussels , november 2023).
- Ricardo Sanchez Prieto participated in the activities of scientific dissemination within the Science Week events with the talk about "Be open about animal Research" (Cuenca and Albacete).
- Ricardo Sanchez Prieto participated in the Crowdfunding campain "IRRADIANDO ESPERANZA" in the University of Castilla La Mancha.
- Guillermo de Carcer, Gema Moreno and cols published article: TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling (Mol Oncol. 2024 Jun;18(6):1531-1551)